It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
As a result – Pfizer alleged – this restricted use of Pfizer's infliximab biosimilar Inflectra, which it originally launched in 2016. Among the anticompetitive practices that Pfizer accused J&J of was contracting with payers and providers to prevent use of Inflectra, with Remicade payer contracts allegedly written to deny reimbursement for Inflectra, apart from cases where J&J’s drug had proven ineffective for patients.